Science ❯ Biotechnology ❯ Gene Therapy

Clinical Trials

uniQure Regulatory Affairs OTOF Gene Mutations Ethical Concerns AMT-130 Therapeutic Candidates Drug Development Hemophilia Treatment Visual Function Restoration Funding Issues COVID-19 Vaccines Manufacturing Processes Regulatory Processes STXBP1 Encephalopathy

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

The agreement deepens Lilly’s push into ophthalmic gene medicines following its October move to buy Adverum Biotechnologies.

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

Capsida Halts STXBP1 Gene Therapy Trial After First Pediatric Participant Dies

Kriya Nets $320 Million Series D as Odyssey Raises $213 Million and Amgen Retools Research Leadership